quantisnow
FeedTopReportsPricing
⌘K
Live feed
16:37:25·7h
INSIDERFiling
Day One Biopharmaceuticals Inc. logo

Director Holles Natalie C. returned 57,310 shares to the company, closing all direct ownership in the company (SEC Form 4) to satisfy tax liability

DAWN· Day One Biopharmaceuticals Inc.
Health Care
Original source

Companies

  • DAWN
    Day One Biopharmaceuticals Inc.
    Health Care

Recent analyst ratings

  • Mar 10UpdateH.C. Wainwright$21.50
  • Jan 13UpdateTD Cowen$34.00
  • Aug 19UpdatePiper Sandler$25.00
  • Oct 9UpdateNeedham$33.00
  • Aug 1UpdateBofA Securities$24.00
  • Apr 24UpdateNeedham$33.00

Related

  • INSIDER7h
    CHIEF EXECUTIVE OFFICER Bender Jeremy returned 1,799,031 shares to the company, closing all direct ownership in the company (SEC Form 4) (for withholding tax)
  • INSIDER7h
    Head of Research and Dev. Vasconcelles Michael returned 4,397 shares to the company, closing all direct ownership in the company (SEC Form 4) (withholding obligation)
  • INSIDER7h
    COO and CFO York Charles N Ii returned 312,025 shares to the company, closing all direct ownership in the company (SEC Form 4) (tax withholding)
  • INSIDER7h
    Gen Counsel & Secretary Dubow Adam returned 72,694 shares to the company, closing all direct ownership in the company (SEC Form 4) to cover taxes
  • INSIDER7h
    Director Ramasastry Saira returned 40,485 shares to the company, closing all direct ownership in the company (SEC Form 4) to cover taxes
  • INSIDER7h
    Director Josey John A. returned 72,292 shares to the company, closing all direct ownership in the company (SEC Form 4) (for withholding tax)
  • INSIDER7h
    SEC Form 4 filed by Director Garland J. Scott (withholding tax)
  • INSIDER7h
    SEC Form 4 filed by Director Dable Habib J to cover withholding tax
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022